https://www.selleckchem.com/pr....oducts/ceftaroline-f
To evaluate the ocular hypotensive efficacy and safety of razuprotafib, a novel Tie2 activator, when used as an adjunct to latanoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Subjects with OAG or OHT and an unmedicated IOP from ≥22 mm Hg to 36 mm Hg were randomized to one of three treatment arms razuprotafib every day (QD) + latanoprost; razuprotafib twice daily (BID) + latanoprost; or latanoprost monotherapy. The primary endpoint was change in mean diurnal IOP from baseline at day 28. A
Like
Comment
Share
